TAK1 inhibitor 5Z-7-oxozeaenol sensitizes neuroblastoma to chemotherapy

Apoptosis

Volumn 18, Issue 10, 2013, Pages 1224-1234

  Fan, Yihui ^a   Cheng, Jin ^a,b   Vasudevan, Sanjeev A ^a   Patel, Roma H ^a   Liang, Li ^c   Xu, Xin ^a   Zhao, Yanling ^a   Jia, Wei ^c   Lu, Fengmin ^b   Zhang, Hong ^c   Nuchtern, Jed G ^a   Kim, Eugene S ^a   Yang, Jianhua ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

5Z 7 oxozeaenol; Chemotherapy; Neuroblastoma; TAK1 inhibitor

Indexed keywords

5Z 7 OXOZEAENOL; CASPASE 3; DOXORUBICIN; ETOPOSIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN SERINE THREONINE KINASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CELL SURVIVAL; CHEMOSENSITIZATION; COLONY FORMATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ETOPOSIDE; FEMALE; HETEROGRAFTS; HUMANS; MAP KINASE KINASE KINASES; MICE; MICE, NUDE; NEUROBLASTOMA; SIGNAL TRANSDUCTION; ZEARALENONE;

EID: 84885427100     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-013-0864-0     Document Type: Article

References (37)

1. Castleberry RP (1997) Neuroblastoma. Eur J Cancer 33:1430-1437 discussion 1437-1438
2. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Simon T, Garaventa A, Castel V, Matthay KK (2009) The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 27:289-297
3. Maris JM (2010) Recent advances in neuroblastoma. N Engl J Med 362:2202-2211
4. Seeger RC (2011) Immunology and immunotherapy of neuroblastoma. Semin Cancer Biol 21:229-237
5. Sen R, Baltimore D (1986) Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell 47:921-928
6. Newton K, Dixit VM (2012) Signaling in innate immunity and inflammation. Cold Spring Harb Perspect Biol 4(3)
7. Oeckinghaus A, Hayden MS, Ghosh S (2011) Crosstalk in NF-kappaB signaling pathways. Nat Immunol 12:695-708
8. Li F, Sethi G (2010) Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta 1805:167-180
9. Aggarwal BB, Sung B (2011) NF-kappaB in cancer: a matter of life and death. Cancer Discov 1:469-471
10. Chaturvedi MM, Sung B, Yadav VR, Kannappan R, Aggarwal BB (2011) NF-kappaB addiction and its role in cancer: 'one size does not fit all'. Oncogene 30:1615-1630
11. Verissimo CS, Molenaar JJ, Fitzsimons CP, Vreugdenhil E (2011) Neuroblastoma therapy: what is in the pipeline? Endocr Relat Cancer 18:R213-231
12. Harper JW, Elledge SJ (2007) The DNA damage response: ten years after. Mol Cell 28:739-745
13. Lee JH, Paull TT (2007) Activation and regulation of ATM kinase activity in response to DNA double-strand breaks. Oncogene 26:7741-7748
14. Sousa FG, Matuo R, Soares DG, Escarqueil AE, Henriques JA, Larsen AK, Saffi J (2012) PARPs and the DNA damage response. Carcinogenesis 33:1433-1440
15. Mortusewicz O, Ame JC, Schreiber V, Leonhardt H (2007) Feedback-regulated poly(ADP-ribosyl)ation by PARP-1 is required for rapid response to DNA damage in living cells. Nucleic Acids Res 35:7665-7675
16. Schreiber V, Dantzer F, Ame JC, de Murcia G (2006) Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 7:517-528
17. Janssens S, Tschopp J (2006) Signals from within: the DNA-damage-induced NF-kappaB response. Cell Death Differ 13:773-784
18. Wu ZH, Miyamoto S (2007) Many faces of NF-kappaB signaling induced by genotoxic stress. J Mol Med (Berl) 85:1187-1202
19. Yamaguchi K, Shirakabe K, Shibuya H, Irie K, Oishi I, Ueno N, Taniguchi T, Nishida E, Matsumoto K (1995) Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 270:2008-2011
20. Chen ZJ, Bhoj V, Seth RB (2006) Ubiquitin, TAK1 and IKK: is there a connection? Cell Death Differ 13:687-692
21. Hayden MS, Ghosh S (2008) Shared principles in NF-kappaB signaling. Cell 132:344-362
22. Sun SC, Ley SC (2008) New insights into NF-kappaB regulation and function. Trends Immunol 29:469-478
23. Shim JH, Xiao C, Paschal AE, Bailey ST, Rao P, Hayden MS, Lee KY, Bussey C, Steckel M, Tanaka N, Yamada G, Akira S, Matsumoto K, Ghosh S (2005) TAK1, but not TAB 1 or TAB 2, plays an essential role in multiple signaling pathways in vivo. Genes Dev 19:2668-2681
24. Wu ZH, Wong ET, Shi Y, Niu J, Chen Z, Miyamoto S, Tergaonkar V (2010) ATM- and NEMO-dependent ELKS ubiquitination coordinates TAK1-mediated IKK activation in response to genotoxic stress. Mol Cell 40:75-86
25. Yang Y, Xia F, Hermance N, Mabb A, Simonson S, Morrissey S, Gandhi P, Munson M, Miyamoto S, Kelliher MA (2011) A cytosolic ATM/NEMO/RIP1 complex recruits TAK1 to mediate the NF-kappaB and p38 mitogen-activated protein kinase (MAPK)/MAPK-activated protein 2 responses to DNA damage. Mol Cell Biol 31:2774-2786
26. Hinz M, Stilmann M, Arslan SC, Khanna KK, Dittmar G, Scheidereit C (2010) A cytoplasmic ATM-TRAF6-cIAP1 module links nuclear DNA damage signaling to ubiquitin-mediated NF-kappaB activation. Mol Cell 40:63-74
27. Jin HS, Lee DH, Kim DH, Chung JH, Lee SJ, Lee TH (2009) cIAP1, cIAP2, and XIAP act cooperatively via nonredundant pathways to regulate genotoxic stress-induced nuclear factor-kappaB activation. Cancer Res 69:1782-1791
28. Liang L, Fan Y, Cheng J, Cheng D, Zhao Y, Cao B, Ma L, An L, Jia W, Su X, Yang J, Zhang H (2013) TAK1 ubiquitination regulates doxorubicin-induced NF-kappaB activation. Cell Signal 25:247-254
29. Melisi D, Xia Q, Paradiso G, Ling J, Moccia T, Carbone C, Budillon A, Abbruzzese JL, Chiao PJ (2011) Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. J Natl Cancer Inst 103:1190-1204
30. Martin SE, Wu ZH, Gehlhaus K, Jones TL, Zhang YW, Guha R, Miyamoto S, Pommier Y, Caplen NJ (2011) RNAi screening identifies TAK1 as a potential target for the enhanced efficacy of topoisomerase inhibitors. Curr Cancer Drug Targets 11:976-986
31. Singh A, Sweeney MF, Yu M, Burger A, Greninger P, Benes C, Haber DA, Settleman J (2012) TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell 148:639-650
32. Ahmed N, Zeng M, Sinha I, Polin L, Wei WZ, Rathinam C, Flavell R, Massoumi R, Venuprasad K (2011) The E3 ligase Itch and deubiquitinase Cyld act together to regulate Tak1 and inflammation. Nat Immunol 12:1176-1183
33. Shang X, Burlingame SM, Okcu MF, Ge N, Russell HV, Egler RA, David RD, Vasudevan SA, Yang J, Nuchtern JG (2009) Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma. Mol Cancer Ther 8:2461-2469
34. Patterson DM, Shohet JM, Kim ES (2011) Preclinical models of pediatric solid tumors (neuroblastoma) and their use in drug discovery. Curr Protoc Pharmacol 14:14-17
35. Tsang PS, Cheuk AT, Chen QR, Song YK, Badgett TC, Wei JS, Khan J (2012) Synthetic lethal screen identifies NF-kB as a target for combination therapy with topotecan for patients with neuroblastoma. BMC Cancer 12:101
36. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-674
37. Ninomiya-Tsuji J, Kajino T, Ono K, Ohtomo T, Matsumoto M, Shiina M, Mihara M, Tsuchiya M, Matsumoto K (2003) A resorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase. J Biol Chem 278:18485-18490